AMLX Q3 2025 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$20M

Operating Income

-$36M

Net Income

-$34M

EPS (Diluted)

$-0.37

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$363M

Total Liabilities

$31M

Stockholders' Equity

$332M

Cash & Equivalents

$225M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$416,000	-100.0%
Gross Profit	-$20M	-$393,000	-4952.2%
Operating Income	-$36M	-$76M	+52.4%
Net Income	-$34M	-$73M	+52.7%